Clear Benefit for Patients with Synovial Sarcoma Demonstrated in Updated Data from Ongoing Phase 1 Trial with ADP-A2M4 Presented at ESMO

NEXT STORY
CK Hutchison prices offering of Chi-Med share capital enabling deconsolidation and confirms its intention to hold Chi-Med as a strategic investment for the long term
PREV STORY
Acasti Pharma Announces Additional Phase 3 Milestones Reached, and Remains on Track to Report Topline Results for TRILOGY 1 in December 2019 and TRILOGY 2 in January 2020
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

ADMA Biologics Resubmits Biologics License Application for RI-002

RAMSEY, N.J. and BOCA RATON, Fla., Oct. 01, 2018 (GLOBE NEWSWIRE) -- ADMA Biologics, ...

author_avatar
NASDAQ Market News

ARASENS trial with darolutamide in combination with docetaxel and androgen deprivation therapy meets primary endpoint of significantly increasing overall survival in patients with metastatic hormone-sensitive prostate cancer

author_avatar
NASDAQ Market News

MPI publishes Annual Report for 2016

Medical Prognosis Institute A/S ("MPI") publishes the Annual Report for 2016. For the complete ...

author_avatar
NASDAQ Market News